MVS Solutions identifies, targets and helps develop strategic alliances, joint ventures, partnering, acquisitions & mergers (M&A) and related relationships on behalf of our clients, ourselves and our partners in the biotech, chemistry, healthcare, life sciences, medical, pharmaceutical, environmental and related industries. The following opportunities are currently available:

Current Opportunities

   Commercialization Partner for Development of Human Heart Failure Detection Technology

Cambridge, Massachusetts (USA) biotechnology company is looking for a commercialization partner and funding assistance for the continuing development of Human Heart Failure Detection Technology. Our unique approach to developing this technology resides first in having clearly identified and categorized human tissue samples through access to full medical records and demographics. Our technology is based on a subtractive hybridization screening analysis (SSH). We have used this analysis approach as a screening tool to develop a focused heart failure microarray containing 1,143 differentially expressed genes. The company provides intellectual property, expertise in pre-clinical screening and testing of NCEs (both GLP and non-GLP), a large animal model for pre-clinical screening and testing of NCEs and our human heart failure as well as large animal model heart failure array to the partnership. Required assistance includes the later stage clinical use for patient enrollment in clinical trials and identification of responders and non-responders, as well as sharing the burden of any additional costs associated with intellectual property patents, regulatory filings, and marketing.

Interested parties call 1.617.283.2182 or Contact Us

   Merger or Acquisition Target For Established Biotech, Pharma & Related

Southern New England biotechnology company is a merger or acquisition target for a biotech, pharma or related company with the capability to fully exploit the technological and market potential of company's platform technology and lead candidate. Target biotech company owns significant intellectual property (IP) for re-engineering biopharma proteins. Although multiple applications include targeted delivery of therapeutic agents and targeted molecular imaging (platform technology), the lead candidate for clinical development is a proprietary single-chain vascular endothelial growth factor (scVEGF) for imaging VEGF receptors in tumor vasculature. Target biotech company has a fully-equipped modern laboratory facility with existing sales including >$4 million in federal grants and a global client base for its existing products and services.

Interested parties call 1.617.283.2182 or Contact Us

   Peptide & Peptidomimetic Therapeutics

Looking for a commercialization partner and funding assistance for the continuing development of peptide and peptide mimetic drugs. Existing drug candidates show promising applications as a vaccine or cancer adjuvant; antimicrobial agent for antibiotic resistant microorganisms; angiogenesis promotion for wound healing; and, in the treatment of Alzheimer's Disease (AD). Therapeutic agents have a strong intellectual property position. Required assistance includes preclinical and early Phase I/II clinical studies. Distribution and manufacturing arrangements also considered.

Interested parties call 1.617.283.2182 or Contact Us

   Novel DNA & Protein Chips

Seeking a commercialization partner for the development and manufacture of pre-printed slides for DNA and related microarrays. Dendron based surface chemistry & nanotechnology has a strong intellectual property position with additional applications in affinity chromatography, immunoassays, biosensors and biochips. Company with strong market presence preferred.

Interested parties call 1.617.283.2182 or Contact Us

   Marine Coatings & Antibiofilm Coatings

Looking for a commercialization partner and co-marketing partnership with leading manufacturers or suppliers of industrial coatings (marine coatings and anti-biofilms). Novel environmentally friendly bioadhesive based coating technology shows promise as a substitute for tributyltin (TBT) based coatings. Assistance required in the co-development and manufacture of coating formulations with broad-spectrum antibiotics. Will consider multiple arrangements for separate market segments.

Interested parties call 1.617.283.2182 or Contact Us

   Manufacturing Facility for Acquisition

Private firm seeks to purchase manufacturing facility, U.S. location only at this time. The facility must include land, building(s) and equipment/machinery. Facilities equipped for biotech, pharmaceutical or medical device operations preferred. Closed plants and turnarounds will be considered. Please provide summary of the operation, type of industry and specific dollar values. Summary should include information on location, value of the building, value of the land, value of any equipment or machinery and amount of receivables.

Interested parties call 1.617.283.2182 or Contact Us

   Hepatitis C Treatment

Private individual seeks technology and other investors to address the poorly served yet expanding hepatitis C market by developing novel medical treatments. The therapeutic market for hepatitis C (HCV), a blood-based viral infection, is estimated to be over $4 billion annually. The company is actively pursuing an additional $5 million for the development of its core technology and will consider acquisition or licensing synergistic technologies.

Interested parties call 1.617.283.2182 or Contact Us

Contact Us for information about how MVS Solutions can identify, target and help develop strategic alliances, joint ventures, partnering, acquisitions, mergers & related relationships on behalf of you and your organization.

Visit our Technology Licensing site for technology licensing opportunities.

All inquiries are held in the strictest of confidence. Nondisclosure and Confidentiality Agreements are available upon request.